147 related articles for article (PubMed ID: 21338391)
1. How KDIGO will (or will not) influence the management of hyperphosphatemia.
Kovesdy CP
Semin Dial; 2011; 24(1):35-6. PubMed ID: 21338391
[No Abstract] [Full Text] [Related]
2. Update on the new Kidney Disease: Improving Global Outcomes (KDIGO) guidelines for mineral and bone disorders (MBD)--a focus on medications.
Raymond CB; Wazny LD; Sood AR
CANNT J; 2010; 20(1):42-6; quiz 47-8. PubMed ID: 20426360
[No Abstract] [Full Text] [Related]
3. Off-label use of phosphate binders in non-dialysis-dependent CKD.
Winkelmayer WC; Chertow GM
Am J Kidney Dis; 2010 Nov; 56(5):813-6. PubMed ID: 20970022
[No Abstract] [Full Text] [Related]
4. Are calcium-based phosphate binders ever preferable in dialysis patients?
Jain N; Reilly RF
Semin Dial; 2014; 27(3):269-72. PubMed ID: 24620781
[No Abstract] [Full Text] [Related]
5. Calcium balance in dialysis is best managed by adjusting dialysate calcium guided by kinetic modeling of the interrelationship between calcium intake, dose of vitamin D analogues and the dialysate calcium concentration.
Gotch F; Levin NW; Kotanko P
Blood Purif; 2010; 29(2):163-76. PubMed ID: 20093823
[TBL] [Abstract][Full Text] [Related]
6. Prevalence of chronic kidney disease-mineral and bone disorder in incident peritoneal dialysis patients and its association with short-term outcomes.
Chuang SH; Wong HC; Vathsala A; Lee E; How PP
Singapore Med J; 2016 Nov; 57(11):603-609. PubMed ID: 26778726
[TBL] [Abstract][Full Text] [Related]
7. [Chronic renal failure causes bone fragility and blood vessel stiffening].
Keronen S; Martola L; Honkanen E
Duodecim; 2012; 128(5):465-74. PubMed ID: 22486062
[TBL] [Abstract][Full Text] [Related]
8. Public health approach to addressing hyperphosphatemia among dialysis patients.
Sehgal AR; Sullivan C; Leon JB; Bialostosky K
J Ren Nutr; 2008 May; 18(3):256-61. PubMed ID: 18410881
[TBL] [Abstract][Full Text] [Related]
9. [Importance of the "adequate blood phosphorus" concept as a risk factor for hyperphosphatemia].
Douthat WG; Alles A; Marinovich S; Tirado S; Peñalba A; Prudkin S
Nefrologia; 2003; 23 Suppl 2():95-9. PubMed ID: 12778863
[TBL] [Abstract][Full Text] [Related]
10. Outcomes associated with phosphorus binders in men with non-dialysis-dependent CKD.
Kovesdy CP; Kuchmak O; Lu JL; Kalantar-Zadeh K
Am J Kidney Dis; 2010 Nov; 56(5):842-51. PubMed ID: 20728255
[TBL] [Abstract][Full Text] [Related]
11. Hyperphosphatemia in renal failure.
Robb M
RN; 2008 Dec; 71(12):26-30; quiz 31. PubMed ID: 19108567
[No Abstract] [Full Text] [Related]
12. Effect of lanthanum carbonate treatment on bone in Japanese dialysis patients with hyperphosphatemia.
Shigematsu T; Tokumoto A; Nakaoka A; Arisaka H
Ther Apher Dial; 2011 Apr; 15(2):176-84. PubMed ID: 21426511
[TBL] [Abstract][Full Text] [Related]
13. A daunting task but largely successful in developing meaningful guidelines.
O'Neill WC
Semin Dial; 2011; 24(1):24-7. PubMed ID: 21338388
[No Abstract] [Full Text] [Related]
14. Target levels for serum phosphorus and parathyroid hormone.
Qunibi W; Kalantar-Zadeh K
Semin Dial; 2011; 24(1):29-33. PubMed ID: 21324001
[No Abstract] [Full Text] [Related]
15. Pathogenesis of bone and mineral related disorders in chronic kidney disease: key role of hyperphosphatemia.
Román-García P; Carrillo-López N; Cannata-Andía JB
J Ren Care; 2009 Mar; 35 Suppl 1():34-8. PubMed ID: 19222729
[TBL] [Abstract][Full Text] [Related]
16. Understanding and managing hyperphosphatemia in patients with chronic renal disease.
Malluche HH; Monier-Faugere MC
Clin Nephrol; 1999 Nov; 52(5):267-77. PubMed ID: 10584989
[TBL] [Abstract][Full Text] [Related]
17. Compliance with objectives based on different guidelines (KDIGO/S.E.N.) and analysis of the individual variability of mineral metabolism in haemodialysis patients in the medium term.
del Pozo-Fernández C; López-Menchero-Martínez R; Álvarez-Avellán L; Albero-Molina MD; Sánchez-Rodríguez L
Nefrologia; 2013; 33(5):675-84. PubMed ID: 24089159
[TBL] [Abstract][Full Text] [Related]
18. [Clinical evidence and treatment for optimum concentration of parathyroid hormone, calcium and phosphate in chronic renal failure].
Hoshino J; Ubara Y; Takaichi K
Clin Calcium; 2004 May; 14(5):731-7. PubMed ID: 15577034
[TBL] [Abstract][Full Text] [Related]
19. Salivary glands: a new player in phosphorus metabolism.
Savica V; Calò LA; Santoro D; Monardo P; Santoro G; Muraca U; Davis PA; Bellinghieri G
J Ren Nutr; 2011 Jan; 21(1):39-42. PubMed ID: 21195917
[TBL] [Abstract][Full Text] [Related]
20. [Parathyroid and bone. Management of parathyroid function and evaluation of bone metabolism in hemodialysis patients].
Goto S; Fukagawa M
Clin Calcium; 2007 Dec; 17(12):1830-4. PubMed ID: 18057657
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
